Hypertension pulmonaire (HTP)

Major advances have been made in recent years in the treatment of pulmonary hypertension with a wide range of available therapeutic option, including prostacyclins, endothelin receptor antagonists, and phosphodiesterase type-5 inhibitors. Results of clinical trials with these compounds have shown that improvements in haemodynamic parameters, exercise capacity as well as WHO functional class might be obtained.